Therapeutic insights at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
52 organizations at BIO-Europe 2026 present work in therapeutic insights: 28 drug developers, 14 investors, 6 service providers and 4 academic, government and non-profit bodies. Between them they bring 75 presentations to the program. Most represented: Merck KGaA (9 on the program), Boehringer Ingelheim (4 on the program), Johnson & Johnson (4 on the program). 17 of them have their own page in this guide. As of Sep 29, 2026.
Format
Top represented
Showing 1–12 of 52 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Merck KGaA Darmstadt, Germany | ◆Platinum Sponsor |
Science and technology company active in healthcare, life science and electronics; operates as EMD Serono and MilliporeSigma in North America. | Talk Mon Nov 9 15:00–16:15 Merck's EMEA Advance Biotech Grant Program Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market. Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Panel Tue Nov 10 14:00–14:45 Immunology under the microscope: New frontiers What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering. Panel Tue Nov 10 16:00–16:45 Unlocking Clinical Trial Systems How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely. Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
Boehringer Ingelheim Ingelheim am Rhein, Germany | ◆Platinum Sponsor |
Family-owned pharmaceutical company developing human and animal health medicines. | Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Talk Tue Nov 10 13:00–14:00 Biologics Manufacturing Excellence How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. |
Johnson & Johnson New Brunswick, NJ | ◇Silver Sponsor |
Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. Panel Tue Nov 10 10:00–10:25 Regulatory Updates for Orphan and Paediatric Medicines How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 13:00–13:45 What's Next for Biomanufacturing Strategies? Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up. |
Novo Nordisk Bagsværd, Denmark | ◆Gold Sponsor |
Danish pharmaceutical company, branded Novo since September 2026, making medicines for diabetes, obesity and rare diseases. | Panel Mon Nov 9 11:00–11:45 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. Business of Biotech Panel Tue Nov 10 15:30–15:55 Accelerating Innovation: Creating the Right Environment for Success in Biopharma Partnerships How to design partnerships that work, from payments tied to research milestones and shared risk to guarding intellectual property while sharing ideas. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. |
Sofinnova Partners Paris, France | |
Life sciences venture capital firm investing from seed to late stage in biotech, medtech and industrial biotech. | Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Why AI that forms hypotheses and guides experiments could mean more drug candidates, not fewer scientists, and how to pick which to pursue. Ecosystem InnovationBusiness of Biotech Panel Mon Nov 9 16:00–16:45 Cell and Gene Therapy: What Should You Know? Where cell and gene therapies stand today, what recent clinical and sales data show, and how funding and partnerships are changing. Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. |
Informa London, United Kingdom | |
Events, publishing and data group that runs BIO-Europe and publishes BioXconomy. | Keynote Mon Nov 9 10:45–11:00 Panel Tue Nov 10 09:00–09:45 Networks or neurons: What’s next in CNS dealmaking? What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop. Panel Wed Nov 11 14:00–14:45 BIO-Europe Media Round-Up: The Stories Shaping Biopharma Right Now Journalists pick out the biggest biopharma news stories and deal trends of the moment and explain what they mean for dealmakers. |
Ipsen Boulogne-Billancourt, France | ◆Platinum Sponsor |
French global biopharmaceutical company focused on oncology, rare diseases and neuroscience. | Panel Mon Nov 9 13:00–14:00 Navigating partnering and business development in a shifting global landscape How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples. Panel Mon Nov 9 13:00–13:45 The therapeutic landscape backed by analyst insights Which disease areas analysts rate most promising for new drugs and investment, and how new science and rule changes are reshaping them. |
A Atrogi Stockholm, Sweden | |
Develops oral small molecules for type 2 diabetes and obesity that increase glucose uptake in skeletal muscle. | Panel Tue Nov 10 16:00–16:45 AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. |
European Investment Bank Luxembourg, Luxembourg | |
The European Union's lending institution, providing loans and venture debt, including to life sciences companies. | Panel Tue Nov 10 14:30–14:55 Investing in Women’s Health: How Can Europe Scale Innovation? How Europe can grow investment in women's health, previewing a European Investment Bank study of the field's research, unmet needs and funding options. Panel Tue Nov 10 11:15–12:15 Women’s Health: Healthcare’s Largest Underserved Market and Biggest Growth Opportunity Why women's health is a large, neglected market, and how much value is lost when medicine is designed around the wrong default patient. Therapeutic InsightsBusiness of Biotech |
Novo Holdings Hellerup, Denmark | |
Life-science investment company that manages the Novo Nordisk Foundation's assets, investing in companies from early-stage biotech to mature healthcare businesses. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. Panel Wed Nov 11 09:00–09:45 Beyond the inhaler: The respiratory market New drugs and targets for asthma, chronic obstructive lung disease and pulmonary fibrosis, and where investors and partners are now putting money. |
UCB Brussels, Belgium | |
Biopharmaceutical company developing and marketing medicines for immunology and neurology. | Panel Tue Nov 10 14:30–14:55 Intellectual Property Strategy in Early-Stage Biomanufacturing: Building Competitive Advantage from Day One Whether young companies should patent a new manufacturing process or keep it secret, and how to show partners their intellectual property holds up. Panel Tue Nov 10 11:15–12:15 Women’s Health: Healthcare’s Largest Underserved Market and Biggest Growth Opportunity Why women's health is a large, neglected market, and how much value is lost when medicine is designed around the wrong default patient. Therapeutic InsightsBusiness of Biotech |
AP Asabys Partners Barcelona, Spain | |
Venture capital firm investing in healthcare and life sciences companies. | Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. |
Instantly find 20 buyers in therapeutic insights
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction